Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer

Area of Science:

• Oncology
• Immunology
• Cancer Research

Background:

• Immune checkpoint blockade (ICB) using PD-1/PD-L1 antibodies has transformed cancer treatment for several malignancies.
• Pancreatic ductal adenocarcinoma (PDAC) remains highly aggressive with poor prognosis, and shows limited response to current ICB therapies.
• The low immunogenicity and immunosuppressive tumor microenvironment in PDAC contribute to resistance against ICB.

Purpose of the Study:

• To review the role of PD-L1 expression and microsatellite instability (MSI) as prognostic and predictive markers in PDAC.
• To explore combination therapies that can enhance the anti-tumor immune response in PDAC.

Main Methods:

• Literature review focusing on PD-L1 expression, MSI, and ICB in PDAC.
• Analysis of existing data on combination treatment strategies.

Main Results:

• PD-L1 expression and MSI are critical factors influencing PDAC immunogenicity and response to therapy.
• Current ICB approaches have shown limited efficacy in PDAC.

Conclusions:

• Targeting PD-L1 and MSI, alongside combination therapies, holds promise for overcoming resistance and improving immune responsiveness in PDAC.
• Combining anti-PD-1/PD-L1 agents with vaccines, chemotherapy, or radiation may enhance the cancer immunity cycle in PDAC.